Clinical Trials

The ACTION study is enrolling newly diagnosed diffuse glioma patients whose tumor harbors the H3 K27M-mutation. The study is a world wide randomized, double-blind, placebo-controlled Phase 3 clinical trial. Treatment with ONC201 begins shortly after completion of radiation therapy. The primary endpoint of the study is overall survival (OS). The study will take place at up to 120 sites in North America, Europe and Asia Pacific. 

If you would like more information about the ACTION study, please contact us at [email protected]

The first-in-human clinical trial for adults with recurrent primary CNS tumors is ongoing at the National Institute of Health and in pediatric CNS tumors with the Pacific Pediatric Neuro-Oncology Consortium.